The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates.

ABSTRACT: HER2-positive breast cancer is an aggressive disease. As a result of the development of specific HER2-targeted therapies, such as trastuzumab, more than 20 years ago, the prognosis of these patients has improved. Metastatic HER2-positive breast cancer patients are achieving better survival rates upon treatment with anti-HER2 therapies than patients with HER2-negative disease. Double HER2 blockade with trastuzumab and pertuzumab combined with a taxane achieved an unprecedented survival of over 57 months in first-line patients. Trastuzumab emtansine, the first antibody-drug conjugate approved for patients in second-line treatment was a potent cytotoxic agent bound to trastuzumab and is currently a standard therapeutic strategy. Despite the progress in treatment development, most patients dev

SUBMITTER: Escriva-de-Romani S 

PROVIDER: S-EPMC10099594 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature